HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.
TransCode Therapeutics Stock Up 4.8 %
Shares of RNAZ stock opened at $0.78 on Thursday. TransCode Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $66.33. The stock’s fifty day moving average price is $5.54 and its two-hundred day moving average price is $237.18.
About TransCode Therapeutics
Read More
- Five stocks we like better than TransCode Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Invest in Small Cap Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Does Downgrade Mean in Investing?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.